Abbisko Cayman Reports Positive Phase II Results for Oral PD-L1 Inhibitor ABSK043 in NSCLC Combination Therapy
Abbisko Cayman Limited announced the preliminary results from the dose escalation phase of its ongoing Phase II clinical study evaluating the oral small-molecule PD-L1 inhibitor ABSK043 in combination with the third-generation EGFR-TKI, firmonertinib, for the treatment of non-small cell lung cancer (NSCLC). The data, presented at the European Society for Medical Oncology Asia Congress 2025 (ESMO Asia 2025), indicated that the combination therapy demonstrated favorable safety and tolerability. Regulatory authorities have agreed to expand the program into a first-line study in treatment-naïve patients with EGFR mutated, PD-L1 positive NSCLC. Abbisko Cayman Limited noted that there is no guarantee that ABSK043 will ultimately be successfully marketed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251208-11947313), on December 08, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。